The estimated Net Worth of Michael J Deppe is at least $7.29 Million dollars as of 26 October 2022. Mr Deppe owns over 15,497 units of Quest Diagnostics stock worth over $7,294,561 and over the last 5 years he sold DGX stock worth over $0.
Mr has made over 3 trades of the Quest Diagnostics stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 15,497 units of DGX stock worth $833,584 on 26 October 2022.
The largest trade he's ever made was exercising 15,497 units of Quest Diagnostics stock on 26 October 2022 worth over $833,584. On average, Mr trades about 1,289 units every 47 days since 2019. As of 26 October 2022 he still owns at least 47,503 units of Quest Diagnostics stock.
You can see the complete history of Mr Deppe stock trades at the bottom of the page.
Michael J. Deppe is the VP, Corp. Controller & Chief Accounting Officer at Quest Diagnostics.
Mr Deppe is 54, he's been the VP and Corp. Controller & Chief Accounting Officer of Quest Diagnostics since . There are 18 older and 3 younger executives at Quest Diagnostics. The oldest executive at Quest Diagnostics, Inc. is Gail Wilensky, 76, who is the Independent Director.
Over the last 21 years, insiders at Quest Diagnostics have traded over $67,426,608 worth of Quest Diagnostics stock and bought 34,000 units worth $1,910,090 . The most active insiders traders include Plc Gsk, James F Iii Flaherty, and Jeffrey M Leiden. On average, Quest Diagnostics executives and independent directors trade stock every 19 days with the average trade being worth of $3,750,703. The most recent stock trade was executed by Michael E Prevoznik on 29 August 2024, trading 32,551 units of DGX stock currently worth $3,118,386.
quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator
Quest Diagnostics executives and other stock owners filed with the SEC include: